POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) – Equities researchers at Brookline Capital Management lifted their FY2023 earnings per share estimates for shares of POINT Biopharma Global in a research report issued on Monday, May 15th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($1.27) for the year, up from their previous estimate of ($1.46). The consensus estimate for POINT Biopharma Global’s current full-year earnings is ($0.88) per share.
POINT Biopharma Global (NASDAQ:PNT – Get Rating) last issued its earnings results on Monday, March 27th. The company reported $1.53 EPS for the quarter, topping the consensus estimate of ($0.26) by $1.79. The firm had revenue of $226.58 million during the quarter, compared to analyst estimates of $260.00 million.
POINT Biopharma Global Price Performance
NASDAQ:PNT opened at $10.45 on Thursday. POINT Biopharma Global has a 12-month low of $5.59 and a 12-month high of $11.13. The firm has a market capitalization of $1.10 billion, a P/E ratio of 12.44 and a beta of 0.14. The business has a 50 day simple moving average of $7.83 and a 200 day simple moving average of $7.50.
Institutional Trading of POINT Biopharma Global
Hedge funds have recently added to or reduced their stakes in the business. Psagot Value Holdings Ltd. Israel bought a new stake in shares of POINT Biopharma Global in the 3rd quarter worth $31,000. Amundi bought a new stake in shares of POINT Biopharma Global in the 4th quarter worth $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of POINT Biopharma Global in the 3rd quarter worth $66,000. E Fund Management Co. Ltd. bought a new stake in shares of POINT Biopharma Global in the 3rd quarter worth $79,000. Finally, Tudor Investment Corp Et Al bought a new stake in shares of POINT Biopharma Global in the 3rd quarter worth $79,000. Institutional investors own 72.77% of the company’s stock.
POINT Biopharma Global Company Profile
POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
- Get a free copy of the StockNews.com research report on POINT Biopharma Global (PNT)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.